Unique ID issued by UMIN | UMIN000000891 |
---|---|
Receipt number | R000001074 |
Scientific Title | Prospective study of tansarterial embolization for hepatocellular carcinoma with Lipiodol added Lecithin. |
Date of disclosure of the study information | 2007/11/15 |
Last modified on | 2007/11/14 20:02:26 |
Prospective study of tansarterial embolization for hepatocellular carcinoma with Lipiodol added Lecithin.
Tansarterial embolization for hepatocellular carcinoma with Lipiodol added Lecithin.
Prospective study of tansarterial embolization for hepatocellular carcinoma with Lipiodol added Lecithin.
Tansarterial embolization for hepatocellular carcinoma with Lipiodol added Lecithin.
Japan |
hepatocellar carcinoma
Hepato-biliary-pancreatic surgery |
Malignancy
NO
Our objectives are improvement in the treatment of the primary hepatocellular carcinoma and improvement of convalescence of transcatheter arterial embolization, in useing the emulsion which added the lecithin (surfactant in Lipiodol).
Safety,Efficacy
Confirmatory
Pragmatic
Phase III
curative effect,response rate,survival time, survival rate
adverse events
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Numbered container method
2
Treatment
Medicine |
Lecithin Group:We use the emulsion which added the lecithin which is a surfactant in Lipiodol for transcatheter arterial embolization.
Non-Lecithin Group:We use the Lipiodol which didn't add the lecithin for transcatheter arterial embolization.
20 | years-old | <= |
85 | years-old | >= |
Male and Female
1:Histologically proven or clinically diagnosed hepatocellular carcinoma in primary lesion.
2:Age20-85
3:Performance Status0-1(ECOG)
4:Life expectancy at least 3 months.
5:Adequate organ and marrow function listed below.
a.White blood cell(WBC):3,000<=WBC<12,000/uL
b.Absolute neutrophil count(Neu):Neu >=1,800/uL
c.Hemoglobin(Hb): Hb>=8.0g/dL
d.Serum creatinine(Cr):W.N.L
e. Electrocardiogram(ECG):normal
6:Do not become the adaptation of resection,transplant,and local treatment in algorithm of HCC treatment.
7:Without contraindication of TAE.
8:The patient who have given written informed consent to participant in this study.
1:The patient with the anamnesis of the drug hypersensitivity.
2:The patient with contraindication of medication(Hydrochloric acid doxorubicin, Lipiodol, Gelpert and lecithin).
3:The patient with contraindication of TAE.
a.Severe liver failure
b.Serum Bilirubin(T-Bil):T-Bil>3mg/dl
c.Large quantities of acites.
4:The patient having the activity-related infectious disease(more than fever 38.0 degrees ).
5:The patient having the a serious complication.
6:Pregnant woman.
7: Patients who are judged inappropriate to be enrolled in this study by the doctor in charge.
60
1st name | |
Middle name | |
Last name | Masakazu Yamamoto |
Tokyo Women's Medical University
Department of Surgery, Institute of Gastroenterology
8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
03-3353-8111
1st name | |
Middle name | |
Last name | Shun-ichi Ariizumi, Yutaka Takahashi , |
Tokyo Women's Medical University
Department of Surgery, Institute of Gastroenterology
8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
03-3353-8111
yutaka@ige.twmu.ac.jp
Women's Medical University
Women's Medical University
Self funding
none
none
none
NO
2007 | Year | 11 | Month | 15 | Day |
Unpublished
2007 | Year | 03 | Month | 17 | Day |
2007 | Year | 04 | Month | 01 | Day |
2009 | Year | 12 | Month | 01 | Day |
2009 | Year | 12 | Month | 01 | Day |
2009 | Year | 12 | Month | 01 | Day |
2009 | Year | 12 | Month | 01 | Day |
2007 | Year | 11 | Month | 14 | Day |
2007 | Year | 11 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001074
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |